HRP20120167T1 - Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva - Google Patents
Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva Download PDFInfo
- Publication number
- HRP20120167T1 HRP20120167T1 HR20120167T HRP20120167T HRP20120167T1 HR P20120167 T1 HRP20120167 T1 HR P20120167T1 HR 20120167 T HR20120167 T HR 20120167T HR P20120167 T HRP20120167 T HR P20120167T HR P20120167 T1 HRP20120167 T1 HR P20120167T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- pyridin
- substituted
- alkyloxy
- dione
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 3
- 150000001408 amides Chemical class 0.000 title 1
- 125000005647 linker group Chemical group 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 67
- 125000001424 substituent group Chemical group 0.000 claims abstract 40
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 35
- 229910052736 halogen Inorganic materials 0.000 claims abstract 30
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 29
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 22
- 150000002367 halogens Chemical class 0.000 claims abstract 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 20
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 19
- -1 pyridinediyl Chemical group 0.000 claims abstract 19
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 14
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 11
- 229910052731 fluorine Chemical group 0.000 claims abstract 10
- 239000011737 fluorine Chemical group 0.000 claims abstract 10
- 125000005843 halogen group Chemical group 0.000 claims abstract 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 9
- 125000005842 heteroatom Chemical group 0.000 claims abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 9
- 239000001257 hydrogen Substances 0.000 claims abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 8
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 8
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 7
- 125000004429 atom Chemical group 0.000 claims abstract 6
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 5
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 15
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims 1
- HSJZYKQURKAJQK-UHFFFAOYSA-N 1-[2-(6-naphthalen-1-ylpyridin-3-yl)oxyethyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2C3=CC=CC=C3C=CC=2)N=C1 HSJZYKQURKAJQK-UHFFFAOYSA-N 0.000 claims 1
- CNAZQJHTBNTVGH-UHFFFAOYSA-N 1-[2-(6-naphthalen-2-ylpyridin-3-yl)oxyethyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2C=C3C=CC=CC3=CC=2)N=C1 CNAZQJHTBNTVGH-UHFFFAOYSA-N 0.000 claims 1
- ASOUFWJYKQEBLA-UHFFFAOYSA-N 1-[2-(6-pyridin-3-ylpyridin-3-yl)oxyethyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2C=NC=CC=2)N=C1 ASOUFWJYKQEBLA-UHFFFAOYSA-N 0.000 claims 1
- WBDAZYIJYCKIQT-UHFFFAOYSA-N 1-[2-(6-pyrimidin-5-ylpyridin-3-yl)oxyethyl]pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2C=NC=NC=2)N=C1 WBDAZYIJYCKIQT-UHFFFAOYSA-N 0.000 claims 1
- QKQWMCPVTGEYLI-UHFFFAOYSA-N 1-[2-[5-(2-fluorophenyl)pyridin-2-yl]oxyethyl]pyrrolidin-2-one Chemical compound FC1=CC=CC=C1C(C=N1)=CC=C1OCCN1C(=O)CCC1 QKQWMCPVTGEYLI-UHFFFAOYSA-N 0.000 claims 1
- LIWBZOFPTIHIAB-UHFFFAOYSA-N 1-[2-[6-(2,3-dichlorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound ClC1=CC=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1Cl LIWBZOFPTIHIAB-UHFFFAOYSA-N 0.000 claims 1
- KYBHEZTTZPPARO-UHFFFAOYSA-N 1-[2-[6-(2,4-difluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=CC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O KYBHEZTTZPPARO-UHFFFAOYSA-N 0.000 claims 1
- ZXZVYJRJZLGJTQ-UHFFFAOYSA-N 1-[2-[6-(2,5-difluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=CC=C(F)C(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 ZXZVYJRJZLGJTQ-UHFFFAOYSA-N 0.000 claims 1
- NGEHZCHNBNMIKO-UHFFFAOYSA-N 1-[2-[6-(2-fluorophenyl)pyridin-3-yl]oxyethyl]azetidin-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CC1 NGEHZCHNBNMIKO-UHFFFAOYSA-N 0.000 claims 1
- NQTZQAQIARQHKC-UHFFFAOYSA-N 1-[2-[6-(2-fluorophenyl)pyridin-3-yl]oxyethyl]piperidin-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCCC1 NQTZQAQIARQHKC-UHFFFAOYSA-N 0.000 claims 1
- YPIQGBPULOKXDY-UHFFFAOYSA-N 1-[2-[6-(2-fluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O YPIQGBPULOKXDY-UHFFFAOYSA-N 0.000 claims 1
- OHQFUVSKROYBDE-UHFFFAOYSA-N 1-[2-[6-(2-fluoropyridin-3-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=NC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O OHQFUVSKROYBDE-UHFFFAOYSA-N 0.000 claims 1
- CPOCSJVIALVNQU-UHFFFAOYSA-N 1-[2-[6-(3,4,5-trifluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=C(F)C(F)=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 CPOCSJVIALVNQU-UHFFFAOYSA-N 0.000 claims 1
- RZQRADIOKVNLFM-UHFFFAOYSA-N 1-[2-[6-(3,4-difluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=C(F)C(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O RZQRADIOKVNLFM-UHFFFAOYSA-N 0.000 claims 1
- MSRGHOCDMCNLBX-UHFFFAOYSA-N 1-[2-[6-(3,4-dimethoxyphenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O MSRGHOCDMCNLBX-UHFFFAOYSA-N 0.000 claims 1
- FSKFZBKDRAMBKW-UHFFFAOYSA-N 1-[2-[6-(3,5-dichlorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound ClC1=CC(Cl)=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 FSKFZBKDRAMBKW-UHFFFAOYSA-N 0.000 claims 1
- AXBXKACDIDKSGC-UHFFFAOYSA-N 1-[2-[6-(3,5-difluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=CC(F)=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 AXBXKACDIDKSGC-UHFFFAOYSA-N 0.000 claims 1
- IKAVZYYFUHRLQU-UHFFFAOYSA-N 1-[2-[6-(3,5-dimethyl-1,2-oxazol-4-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound CC1=NOC(C)=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O IKAVZYYFUHRLQU-UHFFFAOYSA-N 0.000 claims 1
- FNBJLEQSAVSNPI-UHFFFAOYSA-N 1-[2-[6-(3-chloro-4-fluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=C(Cl)C(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O FNBJLEQSAVSNPI-UHFFFAOYSA-N 0.000 claims 1
- QMNWLFLFYIQRFG-UHFFFAOYSA-N 1-[2-[6-(3-chloropyridin-4-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound ClC1=CN=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O QMNWLFLFYIQRFG-UHFFFAOYSA-N 0.000 claims 1
- JPNXWMSUFJGVKE-UHFFFAOYSA-N 1-[2-[6-(3-fluoropyridin-4-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC1=CN=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O JPNXWMSUFJGVKE-UHFFFAOYSA-N 0.000 claims 1
- GCOODUBEBPVLGW-UHFFFAOYSA-N 1-[2-[6-(4-ethoxyphenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(OCC)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O GCOODUBEBPVLGW-UHFFFAOYSA-N 0.000 claims 1
- FWQCSRKKYDXBJB-UHFFFAOYSA-N 1-[2-[6-(4-fluoro-2-methylphenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound CC1=CC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O FWQCSRKKYDXBJB-UHFFFAOYSA-N 0.000 claims 1
- ZKRQEZSJFATACG-UHFFFAOYSA-N 1-[2-[6-(4-fluoro-3-methylphenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=C(F)C(C)=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 ZKRQEZSJFATACG-UHFFFAOYSA-N 0.000 claims 1
- NYKUOEHGVDJNTP-UHFFFAOYSA-N 1-[2-[6-(4-fluorophenyl)pyridin-3-yl]oxyethyl]pyridin-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)C=CC=C1 NYKUOEHGVDJNTP-UHFFFAOYSA-N 0.000 claims 1
- BEBUJPUYZBGOQZ-UHFFFAOYSA-N 1-[2-[6-(4-fluorophenyl)pyridin-3-yl]oxyethyl]pyrrole-2,5-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)C=CC1=O BEBUJPUYZBGOQZ-UHFFFAOYSA-N 0.000 claims 1
- BMCCTPCFPIRPKW-UHFFFAOYSA-N 1-[2-[6-(4-fluorophenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O BMCCTPCFPIRPKW-UHFFFAOYSA-N 0.000 claims 1
- GZVKGAHSKNGCRL-UHFFFAOYSA-N 1-[2-[6-(4-methylthiophen-2-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound CC1=CSC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 GZVKGAHSKNGCRL-UHFFFAOYSA-N 0.000 claims 1
- QWIFHWYLEMGQOX-UHFFFAOYSA-N 1-[2-[6-(4-tert-butylphenyl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(C(C)(C)C)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O QWIFHWYLEMGQOX-UHFFFAOYSA-N 0.000 claims 1
- RFDHDIBQDGJVTE-UHFFFAOYSA-N 1-[2-[6-(6-fluoropyridin-3-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=NC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O RFDHDIBQDGJVTE-UHFFFAOYSA-N 0.000 claims 1
- PAXSIXYVYLBLOO-UHFFFAOYSA-N 1-[2-[6-(6-methoxypyridin-3-yl)pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=NC(OC)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O PAXSIXYVYLBLOO-UHFFFAOYSA-N 0.000 claims 1
- ZBUJWECWURZVLI-UHFFFAOYSA-N 1-[2-[6-[2-(trifluoromethoxy)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC(F)(F)OC1=CC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O ZBUJWECWURZVLI-UHFFFAOYSA-N 0.000 claims 1
- GXZQOMZABOBSJQ-UHFFFAOYSA-N 1-[2-[6-[2-(trifluoromethyl)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC(F)(F)C1=CC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O GXZQOMZABOBSJQ-UHFFFAOYSA-N 0.000 claims 1
- NGKUOLKGLDQLPK-UHFFFAOYSA-N 1-[2-[6-[3-(trifluoromethoxy)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC(F)(F)OC1=CC=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 NGKUOLKGLDQLPK-UHFFFAOYSA-N 0.000 claims 1
- BDQPUVXVBALDDP-UHFFFAOYSA-N 1-[2-[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound FC(F)(F)C1=CC=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 BDQPUVXVBALDDP-UHFFFAOYSA-N 0.000 claims 1
- KKWAPUOVABJBIK-UHFFFAOYSA-N 1-[2-[6-[4-(dimethylamino)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(N(C)C)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O KKWAPUOVABJBIK-UHFFFAOYSA-N 0.000 claims 1
- KZMYEPMXRXYIEG-UHFFFAOYSA-N 1-[2-[6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O KZMYEPMXRXYIEG-UHFFFAOYSA-N 0.000 claims 1
- ZZDLMBFWXWSNKW-UHFFFAOYSA-N 1-[2-[6-[4-(trifluoromethyl)phenyl]pyridin-3-yl]oxyethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)CCC1=O ZZDLMBFWXWSNKW-UHFFFAOYSA-N 0.000 claims 1
- KYMPPFJXSYBKAO-UHFFFAOYSA-N 1-[2-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound C1=CC(F)=CC=C1C1=CSC(NCCN2C(NCC2)=O)=N1 KYMPPFJXSYBKAO-UHFFFAOYSA-N 0.000 claims 1
- XPJDCZWRPUXTIG-UHFFFAOYSA-N 1-[2-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]ethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(F)=CC=C1C1=CSC(NCCN2C(CCC2=O)=O)=N1 XPJDCZWRPUXTIG-UHFFFAOYSA-N 0.000 claims 1
- AVUPXJHMRLBJAU-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]azepan-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCCCC1 AVUPXJHMRLBJAU-UHFFFAOYSA-N 0.000 claims 1
- MMVJIQUSZZSZAO-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]azetidin-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CC1 MMVJIQUSZZSZAO-UHFFFAOYSA-N 0.000 claims 1
- GWBGKZYBFLOVCF-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]piperidin-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCCC1 GWBGKZYBFLOVCF-UHFFFAOYSA-N 0.000 claims 1
- RWIIWQJEHBEIJN-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]piperidine-2,6-dione Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCCC1=O RWIIWQJEHBEIJN-UHFFFAOYSA-N 0.000 claims 1
- MULMGJCQCLQCOR-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]pyridin-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)C=CC=C1 MULMGJCQCLQCOR-UHFFFAOYSA-N 0.000 claims 1
- FBXUGIJTBIOFOY-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]pyrrolidin-2-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCC1 FBXUGIJTBIOFOY-UHFFFAOYSA-N 0.000 claims 1
- KVZHRLYJROSETC-UHFFFAOYSA-N 1-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]pyrrolidine-2,5-dione Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCC1=O KVZHRLYJROSETC-UHFFFAOYSA-N 0.000 claims 1
- VGPSVBCVZJYKHO-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]azepan-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCCCC1 VGPSVBCVZJYKHO-UHFFFAOYSA-N 0.000 claims 1
- MXTBJTIXPHOANZ-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]azetidin-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CC1 MXTBJTIXPHOANZ-UHFFFAOYSA-N 0.000 claims 1
- SSOZNIGOWZZZQH-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]piperidin-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCCC1 SSOZNIGOWZZZQH-UHFFFAOYSA-N 0.000 claims 1
- BQCDCGYCNOHHJI-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]piperidine-2,6-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCCC1=O BQCDCGYCNOHHJI-UHFFFAOYSA-N 0.000 claims 1
- WWPPCIQZRXEOKT-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]pyridin-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)C=CC=C1 WWPPCIQZRXEOKT-UHFFFAOYSA-N 0.000 claims 1
- CJMNTPGFQOTGJE-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]pyrrolidin-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCC1 CJMNTPGFQOTGJE-UHFFFAOYSA-N 0.000 claims 1
- WTKGKLZRNCQUKX-UHFFFAOYSA-N 1-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]pyrrolidine-2,5-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CCC1=O WTKGKLZRNCQUKX-UHFFFAOYSA-N 0.000 claims 1
- OIQXPLGUQBVAOW-UHFFFAOYSA-N 3-[2-[6-(2-fluorophenyl)pyridin-3-yl]oxyethyl]imidazolidine-2,4-dione Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1OCCN1C(=O)NCC1=O OIQXPLGUQBVAOW-UHFFFAOYSA-N 0.000 claims 1
- CZZKVBFLEHYBFU-UHFFFAOYSA-N 3-[2-[6-(4-fluorophenyl)pyridin-3-yl]oxyethyl]imidazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1OCCN1C(=O)NCC1=O CZZKVBFLEHYBFU-UHFFFAOYSA-N 0.000 claims 1
- YJFZXHKBQDDBPD-UHFFFAOYSA-N 3-[2-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]ethyl]imidazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C1=CSC(NCCN2C(NCC2=O)=O)=N1 YJFZXHKBQDDBPD-UHFFFAOYSA-N 0.000 claims 1
- HXYFMPXQQUWFLZ-UHFFFAOYSA-N 3-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]-1,3-thiazolidine-2,4-dione Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)SCC1=O HXYFMPXQQUWFLZ-UHFFFAOYSA-N 0.000 claims 1
- AYBABRDRFBSFNB-UHFFFAOYSA-N 3-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]imidazolidine-2,4-dione Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)NCC1=O AYBABRDRFBSFNB-UHFFFAOYSA-N 0.000 claims 1
- ULMCZCKYQQRUMG-UHFFFAOYSA-N 3-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)OCC1 ULMCZCKYQQRUMG-UHFFFAOYSA-N 0.000 claims 1
- PMDIPYYMTHMDIJ-UHFFFAOYSA-N 3-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)SCC1=O PMDIPYYMTHMDIJ-UHFFFAOYSA-N 0.000 claims 1
- PEMXZDCTOHCQAU-UHFFFAOYSA-N 3-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1CCCC1=CC=C(C=2C=CC(F)=CC=2)N=C1 PEMXZDCTOHCQAU-UHFFFAOYSA-N 0.000 claims 1
- CXOHXDPEHSBBGT-UHFFFAOYSA-N 3-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]imidazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)NCC1=O CXOHXDPEHSBBGT-UHFFFAOYSA-N 0.000 claims 1
- PFCVTWAOYXTQDC-UHFFFAOYSA-N 3-[5-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]pyridin-2-yl]benzonitrile Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2C=C(C=CC=2)C#N)N=C1 PFCVTWAOYXTQDC-UHFFFAOYSA-N 0.000 claims 1
- UDWVBHXHMWISTI-UHFFFAOYSA-N 4-[3-(6-phenylpyridin-3-yl)propyl]thiomorpholin-3-one Chemical compound O=C1CSCCN1CCCC1=CC=C(C=2C=CC=CC=2)N=C1 UDWVBHXHMWISTI-UHFFFAOYSA-N 0.000 claims 1
- YPJBBXMCCKZEPE-UHFFFAOYSA-N 4-[3-[6-(2-chlorophenyl)pyridin-3-yl]propyl]thiomorpholin-3-one Chemical compound ClC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CSCC1 YPJBBXMCCKZEPE-UHFFFAOYSA-N 0.000 claims 1
- OAXPIOMGNSKPNT-UHFFFAOYSA-N 4-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]-1,4-thiazin-3-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CSC=C1 OAXPIOMGNSKPNT-UHFFFAOYSA-N 0.000 claims 1
- IZQRURBHRVAPIL-UHFFFAOYSA-N 4-[3-[6-(2-fluorophenyl)pyridin-3-yl]propyl]thiomorpholin-3-one Chemical compound FC1=CC=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CSCC1 IZQRURBHRVAPIL-UHFFFAOYSA-N 0.000 claims 1
- BMCJXNPKNJNCRA-UHFFFAOYSA-N 4-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]-1,4-thiazin-3-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CSC=C1 BMCJXNPKNJNCRA-UHFFFAOYSA-N 0.000 claims 1
- NZHVDRPPZAJBHW-UHFFFAOYSA-N 4-[3-[6-(4-fluorophenyl)pyridin-3-yl]propyl]thiomorpholin-3-one Chemical compound C1=CC(F)=CC=C1C(N=C1)=CC=C1CCCN1C(=O)CSCC1 NZHVDRPPZAJBHW-UHFFFAOYSA-N 0.000 claims 1
- NRMPNNPERNHOCL-UHFFFAOYSA-N 4-[5-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]pyridin-2-yl]benzonitrile Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2C=CC(=CC=2)C#N)N=C1 NRMPNNPERNHOCL-UHFFFAOYSA-N 0.000 claims 1
- ITTYDXSBJOBDAR-UHFFFAOYSA-N 5-[5-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]pyridin-2-yl]thiophene-2-carbonitrile Chemical compound O=C1CCC(=O)N1CCOC1=CC=C(C=2SC(=CC=2)C#N)N=C1 ITTYDXSBJOBDAR-UHFFFAOYSA-N 0.000 claims 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000001068 Prinzmetal angina Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 claims 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000007087 memory ability Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- PYRMMGDIEFGMHP-UHFFFAOYSA-N n-[3-[5-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]pyridin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N=CC(OCCN3C(CCC3=O)=O)=CC=2)=C1 PYRMMGDIEFGMHP-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Spoj formule I, naznačen time štoA se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje sve skupine CH2 mogu biti supstituirane s jednim ili više istih ili različitih supstituenata R4, te gdje se Y bira između O, S i NR11, a Y je vezan na skupinu Het; Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;X je izravna veza; R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore 4-eročlani do 10-eročlani, monociklički ili biciklički, zasićeni ili nezasićeni prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan ili dva dodatna hetero člana prstena, koje se bira između N, NR12, O, S, SO i SO2, koji mogu biti isti ili različiti, uz uvjet da dva člana prstena iz niza O, S, SO i SO2 ne mogu biti prisutni na susjednim položajima u prstenu, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;R3 se bira između fenila, naftalenila i heteroarila, od kojih svaki može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C2)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, di((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkiloksi)karbon-il-, COOH, CONH2, CN, CF3, H2NSO2- i (C1-C4)-alkil-SO2-;R4 se bira između (C1-C4)-alkila i fluora; R5 se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, di((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkiloksi)karbon-il-, COOH, CONH2, CF3 i (C1-C4)-alkil-SO2-;R8 se bira između halogena, (C1-C4)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, okso, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C2)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, di((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkiloksi)karbonil-, COOH, CONH2, CN, CF3, H2NSO2- i (C1-C4)-alkil-SO2-, gdje sve fenilne i heteroarilne skupine mogu biti međusobno neovisno supstituirane s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi; R11 se bira između vodika, (C1-C4)-alkila i ((C1-C4)-alkil)-CO-;R12 se bira između vodika, (C1-C4)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, ((C1-C4)-alkil
Claims (15)
1. Spoj formule I,
[image]
naznačen time što
A se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje sve skupine CH2 mogu biti supstituirane s jednim ili više istih ili različitih supstituenata R4, te gdje se Y bira između O, S i NR11, a Y je vezan na skupinu Het;
Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
X je izravna veza;
R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore 4-eročlani do 10-eročlani, monociklički ili biciklički, zasićeni ili nezasićeni prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan ili dva dodatna hetero člana prstena, koje se bira između N, NR12, O, S, SO i SO2, koji mogu biti isti ili različiti, uz uvjet da dva člana prstena iz niza O, S, SO i SO2 ne mogu biti prisutni na susjednim položajima u prstenu, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;
R3 se bira između fenila, naftalenila i heteroarila, od kojih svaki može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C2)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, di((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkiloksi)karbon-il-, COOH, CONH2, CN, CF3, H2NSO2- i (C1-C4)-alkil-SO2-;
R4 se bira između (C1-C4)-alkila i fluora;
R5 se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, di((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkiloksi)karbon-il-, COOH, CONH2, CF3 i (C1-C4)-alkil-SO2-;
R8 se bira između halogena, (C1-C4)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, okso, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C2)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, di((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkil)aminokarbonil-, ((C1-C4)-alkiloksi)karbonil-, COOH, CONH2, CN, CF3, H2NSO2- i (C1-C4)-alkil-SO2-, gdje sve fenilne i heteroarilne skupine mogu biti međusobno neovisno supstituirane s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi;
R11 se bira između vodika, (C1-C4)-alkila i ((C1-C4)-alkil)-CO-;
R12 se bira između vodika, (C1-C4)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, ((C1-C4)-alkil)-CO-, (C3-C7)-cikloalkil-CnH2n-CO-, fenil-CnH2n-CO-, heteroaril-CnH2n-CO-, ((C1-C4)-alkil)-O-CO- i fenil-CnH2n-O-CO-, gdje sve fenilne i heteroarilne skupine mogu biti supstituirane s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi;
R13 se bira između vodika, (C1-C4)-alkila i fenil-CnH2n-, gdje fenilna skupina može biti supstituirana s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi, gdje su sve skupine R13 međusobno neovisne i mogu biti iste ili različite;
heteroaril je 5-eročlana ili 6-eročlana, monociklička aromatska skupina, koja sadrži jedan, dva ili tri ista ili različita hetero člana prstena, koje se bira između N, NR13, O i S;
n je 0, 1 ili 2, gdje su svi brojevi n međusobno neovisni i mogu biti isti ili različiti;
u bilo kojem od njegovih stereoizomernih oblika ili smjesi stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol;
uz uvjet da skupina -N(R2)-CO-R1 ne može biti nesupstituirana 2-oksopirolidin-1-ilna skupina ili nesupstituirana 2-oksoimidazolin-1-ilna skupina ako je istodobno skupina R3-X-Het- skupina formule
[image]
u kojoj je veza preko koje je ta skupina vezana na skupinu A prikazana linijom koja polazi s položaja 2 u piridinskom prstenu, gdje se R90 bira između imidazol-1-ila, izoksazol-5-ila, izotiazol-5-ila, 1,2,4-triazol-1-ila, pirazin-2-ila i pirazol-3-ila, od kojih svaki može biti supstituiran s (C1-C4)-alkilom, te koja može biti supstituirana na piridinskom prstenu s do četiri supstituenta, koje se bira između (C1-C4)-alkila, (C1-C4)-alkiloksi i halogena;
te uz uvjet da skupina -N(R2)-CO-R1 ne može biti 1,3-dioksoizoindol-2-ilna skupina formule
[image]
u kojoj je veza preko koje je ta skupina vezana na skupinu A prikazana linijom koja polazi od atoma dušika.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što
R3 se bira između fenila, naftalenila, piridinila, pirimidinila, izoksazolila i tiofenila, od kojih svaki može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, CONH2, CN, CF3 i (C1-C4)-alkil-SO2-;
ili njegova fiziološki prihvatljiva sol.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što
R3 je fenil, koji može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, CONH2, CN, CF3 i (C1-C4)-alkil-SO2-;
ili njegova fiziološki prihvatljiva sol.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što
A se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje se Y bira između O i NH, a Y je vezan na skupinu Het;
Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
X je izravna veza;
R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore zasićeni ili nezasićeni, monociklički 4-eročlani do 7-eročlani prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan dodatni hetero član prstena, kojeg se bira između NR12, O i S, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;
R3 je fenil, koji može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, CONH2, CN, CF3 i (C1-C4)-alkil-SO2-;
R5 se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, CONH2, CF3 i (C1-C4)-alkil-SO2-;
R8 se bira između (C1-C4)-alkila i okso;
R12 se bira između H i (C1-C4)-alkil-;
ili njegova fiziološki prihvatljiva sol.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što
A se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje se Y bira između O i NH, a Y je vezan na skupinu Het;
Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
X je izravna veza;
R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore zasićeni ili nezasićeni, monociklički 4-eročlani do 7-eročlani prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan dodatni hetero član prstena, kojeg se bira između NR12, O i S, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;
R3 je fenil, koji može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, CONH2, CN, CF3 i (C1-C4)-alkil-SO2-;
R5 se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, CONH2, CF3 i (C1-C4)-alkil-SO2-; R8 se bira između (C1-C4)-alkila i okso;
R12 se bira između H i (C1-C4)-alkil-;
ili njegova fiziološki prihvatljiva sol.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što
A se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje se Y bira između O i NH, a Y je vezan na skupinu Het;
Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
X je izravna veza;
R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore zasićeni ili nezasićeni, monociklički 4-eročlani do 7-eročlani prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan dodatni hetero član prstena, kojeg se bira između NR12, O i S, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;
R3 je fenil, supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, CONH2, CN, CF3 i (C1-C4)-alkil-SO2-;
R5 se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, OH, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, NH2, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, ((C1-C4)-alkil)-CONH-, CONH2, CF3 i (C1-C4)-alkil-SO2-;
R8 se bira između (C1-C4)-alkila i okso;
R12 se bira između H i (C1-C4)-alkil-;
ili njegova fiziološki prihvatljiva sol.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što
A se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje se Y bira između O i NH, a Y je vezan na skupinu Het;
Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
X je izravna veza;
R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore zasićeni ili nezasićeni, monociklički 4-eročlani do 7-eročlani prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan dodatni hetero član prstena, kojeg se bira između NR12, O i S, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;
R3 je fenil, koji može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, (C1-C4)-alkiloksi-(C1-C2)-alkil-, (C1-C4)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C4)-alkilmerkapto, (C1-C4)-alkilamino, di((C1-C4)-alkil)amino, CONH2, CN, CF3 i (C1-C4)-alkil-SO2-;
R5 se bira između halogena, (C1-C4)-alkila i CF3;
R8 se bira između (C1-C4)-alkila i okso;
R12 se bira između H i (C1-C4)-alkil-;
ili njegova fiziološki prihvatljiva sol.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time što je Het piridindiilna skupina, koja može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
ili njegova fiziološki prihvatljiva sol.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što ga se bira između
1-(3-(6-(2-fluorfenil)-piridin-3-il)propil)-1H-piridin-2-on,
1-(3-(6-(2-fluorfenil)piridin-3-il)propil)piperidin-2-on,
4-(3-(6-fenilpiridin-3-il)propil)tiomorfolin-3-on,
1-(3-(6-(2-fluorfenil)piridin-3-il)propil)pirolidin-2-on,
1-(3-(6-(2-fluorfenil)piridin-3-il)propil)piperidin-2,6-dion,
1-(3-(6-(2-fluorfenil)piridin-3-il)propil)azepan-2-on,
4-(3-(6-(2-klorfenil)piridin-3-il)propil)tiomorfolin-3-on,
4-(3-(6-(4-fluorfenil)piridin-3-il)propil)tiomorfolin-3-on,
4-(3-(6-(2-fluorfenil)piridin-3-il)propil)tiomorfolin-3-on,
1-(3-(6-(2-fluorfenil)piridin-3-il)propil)pirolidin-2,5-dion,
3-(3-(6-(2-fluorfenil)piridin-3-il)propil)tiazolidin-2,4-dion,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)pirolidin-2-on,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)pirolidin-2,5-dion,
3-(3-(6-(4-fluorfenil)piridin-3-il)propil)imidazolidin-2,4-dion,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)azetidin-2-on,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)piperidin-2-on,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)azepan-2-on,
4-(3-(6-(2-fluorfenil)piridin-3-il)propil)-4H-1,4-tiazin-3-on,
3-(3-(6-(2-fluorfenil)piridin-3-il)propil)imidazolidin-2,4-dion,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)piperidin-2,6-dion,
3-(3-(6-(4-fluorfenil)piridin-3-il)propil)tiazolidin-2,4-dion,
1-(3-(6-(2-fluorfenil)piridin-3-il)propil)azetidin-2-on,
1-(3-(6-(4-fluorfenil)piridin-3-il)propil)-1H-piridin-2-on,
4-(3-(6-(4-fluorfenil)piridin-3-il)propil)-4H-1,4-tiazin-3-on,
1-(2-(6-(2-fluorfenil)piridin-3-iloksi)etil)piperidin-2-on,
1-(2-(6-(2-fluorfenil)piridin-3-iloksi)etil)azetidin-2-on,
1-(2-(6-(2-fluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
3-(2-(4-(4-fluorfenil)tiazol-2-ilamino)etil)imidazolidin-2,4-dion,
3-(2-(6-(2-fluorfenil)piridin-3-iloksi)etil)imidazolidin-2,4-dion,
1-(2-(5-(2-fluorfenil)piridin-2-iloksi)etil)pirolidin-2-on,
1-(2-(4-(4-fluorfenil)tiazol-2-ilamino)etil)pirolidin-2,5-dion,
1-(2-(6-(4-fluorfenil)piridin-3-iloksi)etil)pirol-2,5-dion,
1-(2-(6-(4-fluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-fluorfenil)piridin-3-iloksi)etil)-1H-piridin-2-on,
1-(2-(4-(4-fluorfenil)tiazol-2-ilamino)etil)imidazolidin-2-on,
3-(2-(6-(4-fluorfenil)piridin-3-iloksi)etil)imidazolidin-2,4-dion,
3-(3-(6-(4-fluorfenil)piridin-3-il)propil)-5,5-dimetilimidazolidin-2,4-dion,
3-(3-(6-(4-fluorfenil)piridin-3-il)propil)oksazolidin-2-on,
1-(2(6-(3-klor-4-fluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(6-fluorpiridin-3-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-metiltiofen-2-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3,4,5-trifluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3-trifluormetoksifenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(2-trifluormetoksifenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(6-metoksipiridin-3-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(piridin-3-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-trifluormetoksifenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(2,3-diklorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(2,4-difluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3,4-dimetoksifenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-cijanofenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3-cijanofenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(naftalen-2-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(naftalen-1-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3-acetilaminofenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(2-trifluormetilfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-trifluormetilfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3,5-diklorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3-trifluormetilfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3,4-difluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3,5-difluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-tert-butilfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-etoksifenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(2-fluorpiridin-3-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(2,5-difluorfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-dimetilaminofenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3-klorpiridin-4-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(5-cijanotiofen-2-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3,5-dimetilizoksazol-4-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(3-fluorpiridin-4-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-fluor-2-metilfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion,
1-(2-(6-(4-fluor-3-metilfenil)piridin-3-iloksi)etil)pirolidin-2,5-dion, te
1-(2-(6-(pirimidin-5-il)piridin-3-iloksi)etil)pirolidin-2,5-dion,
ili njihove fiziološki prihvatljive soli.
10. Postupak dobivanja spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegove fiziološki prihvatljive soli, gdje A je -Y-CH2-CH2- (spoj formule Ib), naznačen time što se sastoji u reakciji spoja formule IV sa spojem formule V,
[image]
gdje su Het, X, Y, R1, R2 i R3 definirani kao u patentnim zahtjevima 1 do 9, gdje, uz to, sve funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, a L1 se može nukleofilno supstituirati izlaznom skupinom.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegova fiziološki prihvatljiva sol, naznačen time što je namijenjen upotrebi kao farmaceutsko sredstvo.
12. Farmaceutski pripravak, naznačen time što sadrži djelotvornu dozu najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i/ili njegove fiziološki prihvatljive soli, i farmaceutski prihvatljivu podlogu.
13. Upotreba spoja formule Ia,
[image]
u kojoj
A se bira između -CH2-CH2-CH2- i -Y-CH2-CH2-, gdje sve skupine CH2 mogu biti supstituirane s jednim ili više istih ili različitih supstituenata R4, te gdje se Y bira između O, S i NR11, a Y je vezan na skupinu Het;
Het je piridindiilna ili tiazoldiilna skupina, od kojih svaka može biti supstituirana s jednim ili više istih ili različitih supstituenata R5;
X je izravna veza;
R1 i R2 se međusobno neovisno bira između (C1-C10)-alkila, (C3-C10)-alkenila, (C3-C10)-alkinila, (C3-C10)-cikloalkil-CnH2n-, fenil-CnH2n-, naftalenil-CnH2n- i heteroaril-CnH2n-, a R2 može uz to biti vodik, gdje svaka od (C1-C10)-alkilnih, (C3-C10)-cikloalkilnih, (C3-C10)-alkenilnih i (C3-C10)-alkinilnih skupina može biti supstituirana s jednim ili više istih ili različitih supstituenata R6, svaka od skupina CnH2n može biti supstituirana s jednim ili više istih ili različitih supstituenata, koje se bira između fluora i (C1-C4)-alkila, a svaka od fenilnih, naftalenilnih i heteroarilnih skupina može međusobno neovisno biti supstituirana s jednim ili više istih ili različitih supstituenata R7, ili R1 i R2, zajedno sa skupinom N-CO koja ih nosi, tvore 4-eročlani do 10-eročlani, monociklički ili biciklički, zasićeni ili nezasićeni prsten, koji, uz atom dušika u prstenu koji je dio skupine N-CO, može sadržavati jedan ili dva dodatna hetero člana prstena, koje se bira između N, NR12, O, S, SO i SO2, koji mogu biti isti ili različiti, uz uvjet da dva člana prstena iz niza O, S, SO i SO2 ne mogu biti prisutni na susjednim položajima u prstenu, gdje prsten kojeg tvore R1, R2 i skupina N-CO koja ih nosi može biti supstituiran s jednim ili više istih ili različitih supstituenata R8;
R3 se bira između fenila, naftalenila i heteroarila, od kojih svaki može biti supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C6)-alkila, (C1-C6)-alkiloksi-(C1-C6)-alkil-, OH, (C1-C6)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C3)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C6)-alkilmerkapto, NH2, (C1-C6)-alkilamino, di((C1-C6)-alkil)amino, ((C1-C6)-alkil)-CONH-, ((C1-C6)-alkil)-SO2NH-, di((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkiloksi)karbonil-, COOH, CONH2, CN, CF3, ((C1-C6)-alkil)NHSO2-, di((C1-C6)-alkil)NSO2-, H2NSO2- i (C1-C6)-alkil-SO2-;
R4 se bira između (C1-C6)-alkil, fluora i okso;
R5 se bira između halogena, (C1-C6)-alkila, fenil-CnH2n-, (C1-C6)-alkiloksi-(C1-C3)-alkil-, OH, (C1-C6)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C6)-alkilmerkapto, NH2, (C1-C6)-alkilamino, di((C1-C6)-alkil)amino, ((C1-C6)-alkil)-CONH-, di((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkiloksi)karbonil-, COOH, CONH2, CN, CF3, H2NSO2-, ((C1-C6)-alkil)NHSO2-, di((C1-C6)-alkil)NSO2- i (C1-C6)-alkil-SO2-, gdje fenilna skupina može biti supstituirana s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi;
R6 se bira između fluora, OH, okso, (C1-C6)-alkiloksi, (C1-C6)-alkilmerkapto, di((C1-C6)-alkil)amino, ((C1-C6)-alkil)-CONH-, di((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkiloksi)karbonil-, COOH, CONH2, CN i CF3;
R7 se bira između halogena, (C1-C6)-alkila, (C1-C6)-alkiloksi-(C1-C3)-alkil-, OH, (C1-C6)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C3)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C6)-alkilmerkapto, NH2, (C1-C6)-alkilamino, di((C1-C6)-alkil)amino, ((C1-C6)-alkil)-CONH-, di((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkiloksi)karbonil-, COOH, CONH2, CN, CF3, SF5, H2NSO2-, ((C1-C6)-alkil)NHSO2-, di((C1-C6)-alkil)NSO2- i (C1-C6)-alkil-SO2-;
R8 se bira između halogena, (C1-C6)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, (C1-C6)-alkiloksi-(C1-C3)-alkil-, OH, okso, (C1-C6)-alkiloksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C3)-alkilendioksi, koji može biti supstituiran s jednim ili više atoma fluora, (C1-C6)-alkilmerkapto, NH2, (C1-C6)-alkilamino, di((C1-C6)-alkil)amino, ((C1-C6)-alkil)-CONH-, di((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkil)aminokarbonil-, ((C1-C6)-alkiloksi)karbonil-, COOH, CONH2, CN, CF3, SF5, H2NSO2- i (C1-C6)-alkil-SO2-, gdje sve fenilne i heteroarilne skupine mogu biti međusobno neovisno supstituirane s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi;
R11 se bira između vodika, (C1-C6)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, ((C1-C6)-alkil)-CO-, (C3-C7)-cikloalkil-CnH2n-CO-, fenil-CnH2n-CO- i heteroaril-CnH2n-CO-, gdje sve fenilne i heteroarilne skupine mogu biti supstituirane s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi;
R12 se bira između vodika, (C1-C6)-alkila, (C3-C7)-cikloalkil-CnH2n-, fenil-CnH2n-, heteroaril-CnH2n-, ((C1-C6)-alkil)-CO-, (C3-C7)-cikloalkil-CnH2n-CO-, fenil-CnH2n-CO-, heteroaril-CnH2n-CO-, ((C1-C6)-alkil)-O-CO- i fenil-CnH2n-O-CO-, gdje sve fenilne i heteroarilne skupine mogu biti supstituirane s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi;
R13 se bira između vodika, (C1-C4)-alkila i fenil-CnH2n-, gdje fenilna skupina može biti supstituirana s jednim ili više istih ili različitih supstituenata, koje se bira između halogena, (C1-C4)-alkila, CF3 i (C1-C4)-alkiloksi, gdje su sve skupine R13 međusobno neovisne i mogu biti iste ili različite;
heteroaril je 5-eročlana do 10-eročlana, monociklička ili biciklička aromatska skupina, koja sadrži jedan ili više istih ili različitih hetero članova prstena, koje se bira između N, NR13, O i S;
n je 0, 1, 2 ili 3, gdje su svi brojevi n međusobno neovisni i mogu biti isti ili različiti;
u bilo kojem od njegovih stereoizomernih oblika ili smjesi stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za stimuliranje ekspresije NO sintaze iz endotela.
14. Upotreba spoja u skladu s patentnim zahtjevom 13, ili njegove fiziološki prihvatljive soli, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kardiovaskularnih bolesti, stabilne ili nestabilne angine pektoris, koronarne bolesti srca, bolesti koronarnih arterija, Prinzmetalove angine, akutnog koronarnog sindroma, insuficijencije srca, zatajenja srca, infarkta miokarda, inzulta, tromboze, okluzivne bolesti perifernih arterija, disfunkcije endotela, ateroskleroze, restenoze, oštećenja endotela nakon PTCA, hipertenzije, esencijalne hipertenzije, plućne hipertenzije, sekundarne hipertenzije, renovaskularne hipertenzije, kroničnog glomerulonefritisa, erektilne disfunkcije, ventrikularne aritmije, dijabetesa, komplikacija dijabetesa, nefropatije, retinopatije, angiogeneze, bronhijalne astme, kroničnog zatajenja bubrega, ciroze jetre, osteoporoze, ograničene sposobnosti pamćenja ili ograničene sposobnosti učenja, ili za smanjivanje rizika od kardiovaskularnih pojava kod žena u postmenopauzi ili nakon unosa kontraceptiva.
15. Upotreba u skladu s bilo kojim od patentnih zahtjeva 13 do 14, naznačena time što je spoj formule Ia spoj formule I, u skladu s bilo kojem od patentnih zahtjeva 1 do 9, ili njegova fiziološki prihvatljiva sol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05013870A EP1741709A1 (en) | 2005-06-28 | 2005-06-28 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
PCT/EP2006/005706 WO2007000246A1 (en) | 2005-06-28 | 2006-06-14 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120167T1 true HRP20120167T1 (hr) | 2012-03-31 |
Family
ID=35478793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120167T HRP20120167T1 (hr) | 2005-06-28 | 2012-02-20 | Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva |
Country Status (33)
Country | Link |
---|---|
US (1) | US8518976B2 (hr) |
EP (2) | EP1741709A1 (hr) |
JP (1) | JP5149794B2 (hr) |
KR (1) | KR20080027801A (hr) |
CN (1) | CN101208328B (hr) |
AR (1) | AR054800A1 (hr) |
AT (1) | ATE539072T1 (hr) |
AU (1) | AU2006264049B2 (hr) |
BR (1) | BRPI0613717A2 (hr) |
CA (1) | CA2611953A1 (hr) |
CY (1) | CY1112869T1 (hr) |
DK (1) | DK1899321T3 (hr) |
DO (1) | DOP2006000146A (hr) |
ES (1) | ES2378894T3 (hr) |
GT (1) | GT200600274A (hr) |
HK (1) | HK1122551A1 (hr) |
HR (1) | HRP20120167T1 (hr) |
IL (1) | IL188382A0 (hr) |
MA (1) | MA29552B1 (hr) |
MX (1) | MX2008000044A (hr) |
NO (1) | NO20080523L (hr) |
NZ (1) | NZ565041A (hr) |
PA (1) | PA8683901A1 (hr) |
PE (1) | PE20070102A1 (hr) |
PL (1) | PL1899321T3 (hr) |
PT (1) | PT1899321E (hr) |
RS (1) | RS52266B (hr) |
RU (1) | RU2412181C2 (hr) |
SI (1) | SI1899321T1 (hr) |
TW (1) | TWI378095B (hr) |
UY (1) | UY29640A1 (hr) |
WO (1) | WO2007000246A1 (hr) |
ZA (1) | ZA200710002B (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1939181A1 (en) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
US8815772B2 (en) | 2012-06-29 | 2014-08-26 | E I Du Pont De Nemours And Company | Fungicidal heterocyclic carboxamides |
MX2015014336A (es) | 2013-04-12 | 2016-06-07 | Obschestvo S Ogranichennoi Otveststvennostiyu Pharmentpr | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4429656Y1 (hr) | 1967-03-16 | 1969-12-08 | ||
GB1188416A (en) * | 1968-04-01 | 1970-04-15 | Ici Ltd | Heterocyclic Amines |
GB1231829A (hr) * | 1968-09-19 | 1971-05-12 | ||
GB1341375A (en) * | 1969-11-19 | 1973-12-19 | Smith Kline French Lab | Aminoalkylimidazoles and process for their production |
FR2510997A1 (fr) * | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
US4565814A (en) * | 1983-01-28 | 1986-01-21 | Sanofi | Pyridazine derivatives having a psychotropic action and compositions |
EP0200024B1 (de) * | 1985-04-30 | 1992-07-01 | ARZNEIMITTELWERK DRESDEN GmbH | 3-Cyan-pyridine, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US4710502A (en) * | 1985-11-04 | 1987-12-01 | American Cyanamid Company | 3-heteroarylalkyl-4-quinazolinones |
US4701502A (en) * | 1985-12-13 | 1987-10-20 | E. I. Du Pont De Nemours And Company | Chip resistant primer composition V' |
NL8800998A (nl) * | 1988-04-18 | 1989-11-16 | Cedona Pharm Bv | Werkwijze voor het bereiden van een al of niet gesubstitueerd 4(5)-(omega-aminoalkyl) imidazool. |
TW224974B (hr) * | 1991-07-02 | 1994-06-11 | Hoffmann La Roche | |
GB9127304D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
WO1996018616A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
PT950057E (pt) | 1996-12-10 | 2003-04-30 | Abbott Lab | Enantiomeros de 3-piridilo e sua utilizacao como analgesicos |
US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
WO2000003746A2 (en) | 1998-07-14 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
SE9803518D0 (sv) * | 1998-10-15 | 1998-10-15 | Astra Pharma Prod | Novel compounds |
WO2000051623A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
JP2002255971A (ja) * | 2000-03-31 | 2002-09-11 | Takeda Chem Ind Ltd | 縮合複素環誘導体、その製造法および用途 |
EP1268486A2 (en) | 2000-03-31 | 2003-01-02 | Takeda Chemical Industries, Ltd. | Fused heterocyclic derivatives, their production and use |
WO2002006237A1 (fr) * | 2000-07-18 | 2002-01-24 | Yamanouchi Pharmaceutical Co., Ltd. | Medicament comprenant un derive de dicyanopyridine |
TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
PE20020870A1 (es) | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
CN100480242C (zh) * | 2001-05-29 | 2009-04-22 | 舍林股份公司 | Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用 |
WO2003022821A1 (fr) * | 2001-09-06 | 2003-03-20 | Taisho Pharmaceutical Co., Ltd. | Derive d'heterocycle presentant une activite inhibitrice de l'enzyme de production du 20-hete |
CA2463989C (en) * | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
DE10201240A1 (de) * | 2002-01-15 | 2003-07-24 | Bayer Ag | Substituierte Alkyluracile und ihre Verwendung |
FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2003225964B2 (en) * | 2002-03-28 | 2008-11-20 | Merck Sharp & Dohme Corp. | Substituted 2,3-diphenyl pyridines |
AU2003225305A1 (en) * | 2002-05-08 | 2003-11-11 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
EP1388535A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7186735B2 (en) * | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
EP1388342A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
ATE458731T1 (de) * | 2002-12-20 | 2010-03-15 | Pfizer Prod Inc | Pyrimidin-derivate zur behandlung von anormalem zellwachstum |
US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
CN100360126C (zh) * | 2003-01-31 | 2008-01-09 | 港大科桥有限公司 | 褪黑激素在制备治疗局部缺血性中风的药物中的用途 |
JP2004262890A (ja) * | 2003-03-04 | 2004-09-24 | Taisho Pharmaceut Co Ltd | 20−hete産生阻害作用を有するアゾール誘導体 |
JP2004269469A (ja) * | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
US20040204455A1 (en) | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
EP1471066A1 (en) | 2003-04-24 | 2004-10-27 | Aventis Pharma Deutschland GmbH | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals |
US7538233B2 (en) * | 2003-09-05 | 2009-05-26 | Aventis Pharmaceuticals Inc. | Coumarins as iNOS inhibitors |
WO2005048926A2 (en) * | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
EP1709019B1 (en) * | 2004-01-12 | 2007-08-08 | Applied Research Systems ARS Holding N.V. | Thiazole derivatives and use thereof |
GB0402809D0 (en) * | 2004-02-09 | 2004-03-10 | Glaxo Group Ltd | Chemical compounds |
-
2005
- 2005-06-28 EP EP05013870A patent/EP1741709A1/en not_active Withdrawn
-
2006
- 2006-06-14 WO PCT/EP2006/005706 patent/WO2007000246A1/en active Application Filing
- 2006-06-14 CN CN2006800228986A patent/CN101208328B/zh not_active Expired - Fee Related
- 2006-06-14 ES ES06754352T patent/ES2378894T3/es active Active
- 2006-06-14 CA CA002611953A patent/CA2611953A1/en not_active Abandoned
- 2006-06-14 EP EP06754352A patent/EP1899321B1/en active Active
- 2006-06-14 MX MX2008000044A patent/MX2008000044A/es active IP Right Grant
- 2006-06-14 RS RS20120131A patent/RS52266B/en unknown
- 2006-06-14 KR KR1020077030929A patent/KR20080027801A/ko not_active Application Discontinuation
- 2006-06-14 DK DK06754352.0T patent/DK1899321T3/da active
- 2006-06-14 PL PL06754352T patent/PL1899321T3/pl unknown
- 2006-06-14 PT PT06754352T patent/PT1899321E/pt unknown
- 2006-06-14 AT AT06754352T patent/ATE539072T1/de active
- 2006-06-14 BR BRPI0613717-2A patent/BRPI0613717A2/pt not_active IP Right Cessation
- 2006-06-14 NZ NZ565041A patent/NZ565041A/en not_active IP Right Cessation
- 2006-06-14 SI SI200631277T patent/SI1899321T1/sl unknown
- 2006-06-14 AU AU2006264049A patent/AU2006264049B2/en not_active Ceased
- 2006-06-14 RU RU2008102966/04A patent/RU2412181C2/ru not_active IP Right Cessation
- 2006-06-14 JP JP2008518663A patent/JP5149794B2/ja not_active Expired - Fee Related
- 2006-06-26 DO DO2006000146A patent/DOP2006000146A/es unknown
- 2006-06-26 AR ARP060102736A patent/AR054800A1/es not_active Application Discontinuation
- 2006-06-26 GT GT200600274A patent/GT200600274A/es unknown
- 2006-06-26 TW TW095122876A patent/TWI378095B/zh not_active IP Right Cessation
- 2006-06-27 PE PE2006000748A patent/PE20070102A1/es not_active Application Discontinuation
- 2006-06-28 PA PA20068683901A patent/PA8683901A1/es unknown
- 2006-06-29 UY UY29640A patent/UY29640A1/es not_active Application Discontinuation
-
2007
- 2007-11-20 ZA ZA200710002A patent/ZA200710002B/xx unknown
- 2007-12-18 US US11/958,483 patent/US8518976B2/en not_active Expired - Fee Related
- 2007-12-18 MA MA30487A patent/MA29552B1/fr unknown
- 2007-12-24 IL IL188382A patent/IL188382A0/en unknown
-
2008
- 2008-01-28 NO NO20080523A patent/NO20080523L/no not_active Application Discontinuation
- 2008-12-12 HK HK08113552.5A patent/HK1122551A1/xx not_active IP Right Cessation
-
2012
- 2012-02-20 HR HR20120167T patent/HRP20120167T1/hr unknown
- 2012-03-28 CY CY20121100320T patent/CY1112869T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120167T1 (hr) | Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva | |
ES2739526T3 (es) | Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares | |
RU2018123779A (ru) | Новые соединения | |
ES2674088T3 (es) | Inhibidores de la calicreína plasmática | |
HRP20200379T1 (hr) | Spojevi pirimidindiona protiv srčanih stanja | |
JP2007513915A5 (hr) | ||
JP2007519735A5 (hr) | ||
JP2019504009A5 (hr) | ||
RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
JP2007512349A5 (hr) | ||
RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
JP2017532360A5 (hr) | ||
JP2009524670A5 (hr) | ||
RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
RU2008107264A (ru) | Производные пиразина, полезные в качестве антагонистов аденозинового рецептора | |
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
RU2004112191A (ru) | Лактамсодержащие соединения и их производные в качестве ингибиторов фактора ха | |
RU2010137300A (ru) | Модуляторы бета-амилоида | |
JP2012528166A5 (hr) | ||
BR112014015669B1 (pt) | Compostos derivados de piridinona e pirimidinona, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para o tratamento ou prevenção de uma doença tromboembólica | |
AR044499A1 (es) | Pirimidinas sustituidas con indano inhibidoras de la replicacion del hiv | |
HRP20140115T1 (hr) | Inhibitori poli(adp-riboza)polimeraza | |
RU2009114857A (ru) | Гетероциклические органические соединения | |
CA2522435A1 (en) | Inhibitors of akt activity |